TICKERNERD
Menu
SCYXSCYXHealthcare · Drug Manufacturers - Specialty & Generic

SCYX Stock Forecast: SCYNEXIS, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$4.60
−4.96% on the day

The 3 Wall Street analysts covering SCYNEXIS, Inc. hold a median 12-month price target of $33 — +617.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$48.2M
Ticker Nerd rank
41 / 100
Median analyst target
$33
Analysts covering
3
Revenue$235K−82.8% y/y
Operating income−$7.8M
Net income$7.4M
Free cash flow−$14.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.2%
1M
−11.2%
YTD
−9.0%
1Y
−48.7%
From 52W high
−48.7%
From 52W low
+28.9%
$3.57
$8.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SCYX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SCYNEXIS, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Size
82
Volatility
67
Revisions
53
Quality
47
Momentum
41
Issuance
38
Accruals
15
Value
11

Growth (87): Sales and profits are climbing, and climbing faster than before.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SCYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SCYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00Oct 25Jan 26Apr 26Jul 26SCYXHigh $45Median $33Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $32Median $33High $45

The green dot is the last close — the median target sits +617.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026GuggenheimMaintainsBuy$24 → $33
28 Oct 2025GuggenheimMaintainsBuy$4.00 → $3.00
28 Oct 2025GuggenheimMaintainsBuy—
1 Apr 2024Cantor FitzgeraldReiteratesOverweight—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight—
3 Apr 2023GuggenheimMaintainsBuy—
3 Apr 2023Ladenburg ThalmannReiteratesBuy—
1 Mar 2023GuggenheimInitiatesBuy—
21 Oct 2022Brookline CapitalAssumesBuy$8.00
13 May 2022HC Wainwright & Co.MaintainsBuy—
31 Mar 2022HC Wainwright & Co.MaintainsBuy—
7 June 2021Aegis CapitalMaintainsBuy—
12 Apr 2021Aegis CapitalMaintainsBuy—
22 Jan 2021GuggenheimInitiatesBuy—
6 Jan 2021Cantor FitzgeraldInitiatesOverweight—
28 Dec 2020HC Wainwright & Co.ReiteratesBuy—
25 Nov 2020Aegis CapitalMaintainsBuy—
25 Nov 2020Brean CapitalInitiatesBuy—
25 Nov 2020Canaccord GenuityInitiatesBuy—
25 Nov 2020GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCYX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SCYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, SCYNEXIS, Inc. returned −48.7% against +17.5% for the S&P 500, dividends included.

SCYX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26SCYXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SCYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

SCYNEXIS, Inc. (SCYX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.9×

Cheaper than 71% of US stocks

Price / sales
2.5×

Cheaper than 47% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−82.8%

Higher than 3% of US stocks

Earnings growth (YoY)
−82.8%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−3308.5%

Higher than 3% of US stocks

Net margin
−53.3%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−18.4%

Higher than 32% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SCYNEXIS, Inc. (SCYX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SCYNEXIS, Inc. has a market value of $48.2M and an enterprise value of −$4.0M.

  • Revenue in the twelve months to 30 June 2026: $19.2M. The latest quarter shrank 82.8% year on year.

  • Net income over the same four quarters: −$10.2M, a −53.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$13.3M.

  • Shares outstanding: 9.9M.

  • Trailing P/E: 0.9×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • SCYNEXIS, Inc. employs 18 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SCYX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SCYXSCYNEXIS, Inc.$48.2M
41
ZYBTZhengye Biotechnology Holding Ltd.$46.1M
49
IXHLIncannex Healthcare, Inc.$39.0M
25
TLPHTalphera, Inc.$62.1M
42
INCRInterCure Ltd.$62.3M
9
CPHIChina Pharma Holdings, Inc.$32.7M
49
RMTIRockwell Medical, Inc.$31.4M
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SCYNEXIS, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SCYX news & analysis

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

GlobeNewsWire · 10 Sept 2026positive

SCYNEXIS announced the appointment of Sanjay Subramanian as Chief Financial Officer. Subramanian is described as an accomplished biopharmaceutical finance executive with extensive experience in capital markets activities, strategic transactions, and growth across public companies.

Why it matters — A SCYX watcher would care because the appointment of a finance executive with deep capital markets and strategic transaction experience could strengthen the company's financial leadership, which is relevant to its operations and future growth.

SCYNEXIS to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company, announced on September 1, 2026, that it will participate in upcoming investor conferences. The company said it would take part in these events.

Why it matters — A SCYNEXIS watcher would care because participation in investor conferences gives the company a platform to present its business and pipeline to the investment community.

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 25 Aug 2026neutral

SCYNEXIS announced the grant of an inducement equity award to a new Senior Director, dated August 24, 2026, in connection with the commencement of the employee's employment. The award was approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement for the employee to accept the position.

Why it matters — This signals SCYNEXIS is bringing on a new senior executive with an equity incentive, which may be of interest to investors tracking the company's leadership and hiring activity.

FAQ

Frequently asked questions about SCYX stock

What is the SCYX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering SCYNEXIS, Inc. have a median 12-month price target of $33, with estimates ranging from $32 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SCYX stock a buy right now?

Of the 3 analysts covering SCYNEXIS, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SCYNEXIS, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SCYX?

As at 12 Sept 2026, SCYNEXIS, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will SCYX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +617.4% from the last close, and Ticker Nerd's factor model ranks SCYNEXIS, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SCYX stock forecast for 2030?

No analyst covering SCYNEXIS, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $45 over the next 12 months.

How has SCYX stock performed over the past year?

SCYNEXIS, Inc. returned -48.7% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SCYNEXIS, Inc. do?

SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases.

What is the latest news on SCYX?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer". SCYNEXIS announced the appointment of Sanjay Subramanian as Chief Financial Officer. Subramanian is described as an accomplished biopharmaceutical finance executive with extensive experience in capital markets activities, strategic transactions, and growth across public companies.

Company

About SCYNEXIS, Inc.

SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases. The company markets BREXAFEMME for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, while also advancing investigational candidates such as ibrexafungerp and SCY-247 for broader antifungal and infectious disease applications. SCYNEXIS works across drug development, commercialization, and collaborative partnerships to support the treatment and prevention of serious infections with limited options. Headquartered in Jersey City, New Jersey, the company operates in the specialty pharmaceuticals segment of the healthcare market and serves as a focused biotechnology platform centered on anti-infective innovation.

CEO Dr. David Gonzalez Angulo M.D. · 18 employees · United States · https://www.scynexis.com